Evguenia MBA - Sera Prognostics CEO President

SERA Stock  USD 7.44  0.70  10.39%   

CEO

Evguenia MBA is CEO President of Sera Prognostics
Age 50
Address 2749 East Parleys Way, Salt Lake City, UT, United States, 84109
Phone801 990 0520
Webhttps://seraprognostics.com

Sera Prognostics Management Efficiency

The company has return on total asset (ROA) of (0.2666) % which means that it has lost $0.2666 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4958) %, meaning that it created substantial loss on money invested by shareholders. Sera Prognostics' management efficiency ratios could be used to measure how well Sera Prognostics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 12, 2024, Return On Tangible Assets is expected to decline to -0.4. In addition to that, Return On Capital Employed is expected to decline to -0.58. At present, Sera Prognostics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 980.1 K, whereas Total Assets are forecasted to decline to about 87.3 M.
Sera Prognostics currently holds 1.86 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Sera Prognostics has a current ratio of 14.5, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Sera Prognostics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 7 records

CEO Age

John AballiExagen Inc
39
Christopher HallPersonalis
55
Brian HullingerPsychemedics
56
Timothy DamadianFonar
60
John HannaCaredx Inc
44
Peter MaagCaredx Inc
57
Keith SullivanNeuronetics
66
Sera Prognostics, Inc., a womens health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. Sera Prognostics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 113 people. Sera Prognostics (SERA) is traded on NASDAQ Exchange in USA. It is located in 2749 East Parleys Way, Salt Lake City, UT, United States, 84109 and employs 55 people. Sera Prognostics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Sera Prognostics Leadership Team

Elected by the shareholders, the Sera Prognostics' board of directors comprises two types of representatives: Sera Prognostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sera. The board's role is to monitor Sera Prognostics' management team and ensure that shareholders' interests are well served. Sera Prognostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sera Prognostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Benjamin JD, General Counsel
Steven Graves, CoFounder Board
Sean MD, CoFounder Board
MS MD, Executive Director
John Boniface, Chief Officer
Paul Kearney, Chief Officer
Evguenia MBA, CEO President
MBA MBA, Chief Officer
Michael MD, Chief Officer
Robert Harrison, Chief Officer
Nadia Altomare, Chief Officer
Austin Aerts, Chief Officer

Sera Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sera Prognostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Sera Prognostics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sera Prognostics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sera Prognostics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sera Prognostics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sera Prognostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Sera Stock refer to our How to Trade Sera Stock guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sera Prognostics. If investors know Sera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sera Prognostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.99)
Revenue Per Share
0.003
Quarterly Revenue Growth
(0.31)
Return On Assets
(0.27)
Return On Equity
(0.50)
The market value of Sera Prognostics is measured differently than its book value, which is the value of Sera that is recorded on the company's balance sheet. Investors also form their own opinion of Sera Prognostics' value that differs from its market value or its book value, called intrinsic value, which is Sera Prognostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sera Prognostics' market value can be influenced by many factors that don't directly affect Sera Prognostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sera Prognostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sera Prognostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sera Prognostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.